{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:24:35Z","timestamp":1793053475226,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012538","name":"The Swedish Cancer Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012538","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Swedish Foundation for Higher Education and Cooperation"},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzhen","doi-asserted-by":"crossref","award":["SZSM201412014"],"award-info":[{"award-number":["SZSM201412014"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Science and Technology Foundation of Shenzhen","award":["JCYJ20170307095620828, JCYJ20160422145718224, JCYJ20170412155231633, JSGG20170414104216477, and JCYJ20150402152130696"],"award-info":[{"award-number":["JCYJ20170307095620828, JCYJ20160422145718224, JCYJ20170412155231633, JSGG20170414104216477, and JCYJ20150402152130696"]}]},{"name":"The Shenzhen Urology Minimally Invasive Engineering Centre","award":["GCZX2015043016165448"],"award-info":[{"award-number":["GCZX2015043016165448"]}]},{"name":"The Shenzhen Public Service Platform on Tumor Precision Medicine and Molecular Diagnosis"},{"name":"The Shenzhen Cell Therapy Public Service Platform"},{"name":"Olympia Diagnostics, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Heterogeneity of prostate cancer (PCa) contributes to inaccurate cancer screening and diagnosis, unnecessary biopsies, and overtreatment. We intended to develop non-invasive urine tests for accurate PCa diagnosis to avoid unnecessary biopsies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Using a machine learning program, we identified a 25-Gene Panel classifier for distinguishing PCa and benign prostate. A non-invasive test using pre-biopsy urine samples collected without digital rectal examination (DRE) was used to measure gene expression of the panel using cDNA preamplification followed by real-time qRT-PCR. The 25-Gene Panel urine test was validated in independent multi-center retrospective and prospective studies. The diagnostic performance of the test was assessed against the pathological diagnosis from biopsy by discriminant analysis. Uni- and multivariate logistic regression analysis was performed to assess its diagnostic improvement over PSA and risk factors. In addition, the 25-Gene Panel urine test was used to identify clinically significant PCa. Furthermore, the 25-Gene Panel urine test was assessed in a subset of patients to examine if cancer was detected after prostatectomy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The 25-Gene Panel urine test accurately detected cancer and benign prostate with AUC of 0.946 (95% CI 0.963\u20130.929) in the retrospective cohort (<jats:italic>n<\/jats:italic>\u2009=\u2009614), AUC of 0.901 (0.929\u20130.873) in the prospective cohort (<jats:italic>n<\/jats:italic>\u2009=\u2009396), and AUC of 0.936 (0.956\u20130.916) in the large combination cohort (<jats:italic>n<\/jats:italic>\u2009=\u20091010). It greatly improved diagnostic accuracy over PSA and risk factors (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). When it was combined with PSA, the AUC increased to 0.961 (0.980\u20130.942). Importantly, the 25-Gene Panel urine test was able to accurately identify clinically significant and insignificant PCa with AUC of 0.928 (95% CI 0.947\u20130.909) in the combination cohort (<jats:italic>n<\/jats:italic>\u2009=\u2009727). In addition, it was able to show the absence of cancer after prostatectomy with high accuracy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The 25-Gene Panel urine test is the first highly accurate and non-invasive liquid biopsy method without DRE for PCa diagnosis. In clinical practice, it may be used for identifying patients in need of biopsy for cancer diagnosis and patients with clinically significant cancer for immediate treatment, and potentially assisting cancer treatment follow-up.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-020-01834-0","type":"journal-article","created":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T02:03:03Z","timestamp":1606788183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up"],"prefix":"10.1186","volume":"18","author":[{"given":"Heather","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heqiu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Simoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan H. B.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taolin","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanlong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishtman","family":"Dizeyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per-Anders","family":"Abrahamsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Kenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kefeng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny L.","family":"Persson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingwu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,1]]},"reference":[{"issue":"6","key":"1834_CR1","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1177\/1557988318798279","volume":"12","author":"HE Taitt","year":"2018","unstructured":"Taitt HE. Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am J Mens Health. 2018;12(6):1807\u201323.","journal-title":"Am J Mens Health"},{"issue":"3","key":"1834_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/diagnostics6030027","volume":"6","author":"CL Tonry","year":"2016","unstructured":"Tonry CL, Leacy E, Raso C, et al. The role of proteomics in biomarker development for improved patient diagnosis and clinical decision making in prostate cancer. Diagnostics (Basel). 2016;6(3):27.","journal-title":"Diagnostics (Basel)"},{"issue":"9","key":"1834_CR3","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1158\/1078-0432.CCR-04-1919","volume":"11","author":"GI Botchkina","year":"2005","unstructured":"Botchkina GI, Kim RH, Botchkina IL, Kirshenbaum A, Frischer Z, Adler HL. Noninvasive detection of prostate cancer by quantitative analysis of telomerase activity. Clin Cancer Res. 2005;11(9):3243\u20139.","journal-title":"Clin Cancer Res"},{"key":"1834_CR4","doi-asserted-by":"publisher","unstructured":"Witherspoon L, Breau RH, Lavall\u00e9e LT. Evidence-based approach to active surveillance of prostate cancer. World J Urol. 2019;6. https:\/\/doi.org\/10.1007\/s00345-019-02662-5.","DOI":"10.1007\/s00345-019-02662-5"},{"key":"1834_CR5","doi-asserted-by":"publisher","unstructured":"Osses DF, Roobol MJ, Schoots IG. Prediction medicine: biomarkers, risk calculators and magnetic resonance imaging as risk stratification tools in prostate cancer diagnosis. Int J Mol Sci. 2019; 20(7). doi: https:\/\/doi.org\/10.3390\/ijms20071637.","DOI":"10.3390\/ijms20071637"},{"issue":"Suppl 4","key":"1834_CR6","doi-asserted-by":"publisher","first-page":"S436","DOI":"10.21037\/tau.2018.07.01","volume":"7","author":"N Raja","year":"2018","unstructured":"Raja N, Russell CM, George AK. Urinary markers aiding in the detection and risk stratification of prostate cancer. Transl Androl Urol. 2018;7(Suppl 4):S436\u201342.","journal-title":"Transl Androl Urol"},{"issue":"2","key":"1834_CR7","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.juro.2012.04.143","volume":"189","author":"M Truong","year":"2013","unstructured":"Truong M, Yang B, Jarrard DF. Towards the detection of prostate cancer in urine: a critical analysis. J Urol. 2013;189(2):422\u20139.","journal-title":"J Urol"},{"issue":"1","key":"1834_CR8","doi-asserted-by":"publisher","first-page":"6653","DOI":"10.1038\/s41598-018-24424-w","volume":"8","author":"F Matin","year":"2018","unstructured":"Matin F, Jeet V, Moya L, et al. A plasma biomarker panel of four microRNAs for the diagnosis of prostate cancer. Sci Rep. 2018;8(1):6653.","journal-title":"Sci Rep"},{"issue":"6","key":"1834_CR9","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1158\/1055-9965.EPI-15-1223","volume":"25","author":"RS Kelly","year":"2016","unstructured":"Kelly RS, Heiden MV, Giovannucci EL, Mucci LA. Metabolomic biomarkers of prostate cancer: prediction, diagnosis, progression, prognosis and recurrence. Cancer Epidemiol Biomark Prev. 2016;25(6):887\u2013906.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"6","key":"1834_CR10","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.euf.2017.02.018","volume":"4","author":"J Freds\u00f8e","year":"2018","unstructured":"Freds\u00f8e J, Rasmussen AKI, Thomsen AR, et al. Diagnostic and prognostic microRNA biomarkers for prostate cancer in cell-free urine. Eur Urol Focus. 2018;4(6):825\u201333.","journal-title":"Eur Urol Focus"},{"issue":"1","key":"1834_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/pcan.2009.31","volume":"13","author":"T Jamaspishvili","year":"2010","unstructured":"Jamaspishvili T, Kral M, Khomeriki I, et al. Urine markers in monitoring for prostate cancer. Prostate Cancer Prostatic Dis. 2010;13(1):12\u20139.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"1834_CR12","first-page":"105","volume":"72","author":"DM Carrion","year":"2019","unstructured":"Carrion DM, G\u00f3mez Rivas J, \u00c1lvarez-Maestro M, Mart\u00ednez-Pi\u00f1eiro L. Biomarkers in prostate cancer management. Is there something new? Arch Esp Urol. 2019;72(2):105\u201315.","journal-title":"Arch Esp Urol"},{"issue":"2","key":"1834_CR13","first-page":"116","volume":"72","author":"S Fuessel","year":"2019","unstructured":"Fuessel S, Wirth MP. New markers in prostate cancer: genomics. Arch Esp Urol. 2019;72(2):116\u201325.","journal-title":"Arch Esp Urol"},{"key":"1834_CR14","volume":"30","author":"A Vickers","year":"2019","unstructured":"Vickers A, Carlsson SV. Toward responsible, informed decision making for prostate cancer treatment decisions. J Clin Oncol. 2019;30:JCO1900989.","journal-title":"J Clin Oncol"},{"key":"1834_CR15","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/nrurol.2012.185","volume":"9","author":"LK Boyd","year":"2012","unstructured":"Boyd LK, Mao X, Lu Y. The complexity of prostate cancer: genomic alterations and heterogeneity. Nature Reviews Urol. 2012;9:652\u201364.","journal-title":"Nature Reviews Urol"},{"issue":"16","key":"1834_CR16","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1158\/0008-5472.CAN-10-0021","volume":"70","author":"Y Wang","year":"2010","unstructured":"Wang Y, Xia XQ, Jia Z, Sawyers A, et al. In silico estimates of tissue components in surgical samples based on expression profiling data. Cancer Res. 2010;70(16):6448\u201355.","journal-title":"Cancer Res"},{"issue":"7","key":"1834_CR17","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1158\/0008-5472.CAN-10-2585","volume":"71","author":"Z Jia","year":"2011","unstructured":"Jia Z, Wang Y, Sawyers A, Yao H, et al. Diagnosis of prostate cancer using differentially expressed genes in stroma. Cancer Res. 2011;71(7):2476\u201387.","journal-title":"Cancer Res"},{"key":"1834_CR18","doi-asserted-by":"publisher","first-page":"45219","DOI":"10.1038\/srep45219","volume":"7","author":"T Kroneis","year":"2017","unstructured":"Kroneis T, Kroneis E, Andersson D, Dolatabadi S, St\u00e5hlberg A. Global preamplification simplifies targeted mRNA quantification. Sci Rep. 2017;7:45219.","journal-title":"Sci Rep"},{"issue":"8","key":"1834_CR19","doi-asserted-by":"publisher","first-page":"10115","DOI":"10.1007\/s13277-015-4619-0","volume":"37","author":"K Xiao","year":"2016","unstructured":"Xiao K, Guo J, Zhang X, et al. Use of two gene panels for prostate cancer diagnosis and patient risk stratification. Tumour Biol. 2016;37(8):10115\u201322.","journal-title":"Tumour Biol"},{"issue":"3","key":"1834_CR20","first-page":"1471","volume":"38","author":"J Guo","year":"2018","unstructured":"Guo J, Yang J, Zhang X, et al. A panel of biomarkers for diagnosis of prostate cancer using urine samples. Anticancer Res. 2018;38(3):1471\u20137.","journal-title":"Anticancer Res"},{"key":"1834_CR21","doi-asserted-by":"crossref","unstructured":"Breiman L. Random forests. Machine Learning. 45(1):5\u201332.","DOI":"10.1023\/A:1010933404324"},{"issue":"1","key":"1834_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.tranon.2017.12.002","volume":"11","author":"S Zhao","year":"2018","unstructured":"Zhao S, Yu J, Wang L. Machine learning based prediction of brain metastasis of patients with IIIA-N2 lung adenocarcinoma by a three-miRNA signature. Transl Oncol. 2018;11(1):157\u201367.","journal-title":"Transl Oncol"},{"issue":"1","key":"1834_CR23","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","volume":"70","author":"PA Humphrey","year":"2016","unstructured":"Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol. 2016;70(1):106\u201319.","journal-title":"Eur Urol"},{"issue":"5","key":"1834_CR24","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1016\/j.juro.2011.06.057","volume":"186","author":"S Loeb","year":"2011","unstructured":"Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol. 2011;186(5):1830\u20134.","journal-title":"J Urol"},{"key":"1834_CR25","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.2147\/OTT.S194138","volume":"12","author":"C Song","year":"2019","unstructured":"Song C, Chen H, Song C. Research status and progress of the RNA or protein biomarkers for prostate cancer. Onco Targets Ther. 2019;12:2123\u201336.","journal-title":"Onco Targets Ther"},{"key":"1834_CR26","doi-asserted-by":"publisher","unstructured":"Neuhaus J, Yang B. Liquid Biopsy Potential Biomarkers in Prostate Cancer. Diagnostics (Basel). 2018;8(4):68. https:\/\/doi.org\/10.3390\/diagnostics8040068.","DOI":"10.3390\/diagnostics8040068"},{"issue":"1","key":"1834_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.eururo.2015.04.039","volume":"70","author":"SA Tomlins","year":"2016","unstructured":"Tomlins SA, Day JR, Lonigro RJ, et al. Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment. Eur Urol. 2016;70(1):45\u201353.","journal-title":"Eur Urol"},{"issue":"1","key":"1834_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1541-0420.2005.00420.x","volume":"62","author":"MS Pepe","year":"2006","unstructured":"Pepe MS, Cai T, Longton G. Combining predictors for classification using the area under the receiver operating characteristic curve. Biometrics. 2006;62(1):221\u20139.","journal-title":"Biometrics."},{"key":"1834_CR29","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1158\/0008-5472.CAN-15-2340","volume":"76","author":"R Miftakhova","year":"2016","unstructured":"Miftakhova R, Hedblom A, Semenas J, et al. Cyclin A1 and P450 aromatase promote homing and growth of stem-like prostate cancer cells to bone marrow. Cancer Res. 2016;76:2453\u201364.","journal-title":"Cancer Res"},{"issue":"2","key":"1834_CR30","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1080\/21541264.2018.1539615","volume":"10","author":"MD Galbraith","year":"2019","unstructured":"Galbraith MD, Bender H, Espinosa JM. Therapeutic targeting of transcriptional cyclin-dependent kinases. Transcription. 2019;10(2):118\u201336.","journal-title":"Transcription."},{"issue":"1","key":"1834_CR31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13018-019-1101-5","volume":"14","author":"D Luo","year":"2019","unstructured":"Luo D, Ren H, Zhang W, Xian H, Lian K, Liu H. Clinicopathological and prognostic value of hypoxia-inducible factor-1\u03b1 in patients with bone tumor: a systematic review and meta-analysis. J Orthop Surg Res. 2019;14(1):56.","journal-title":"J Orthop Surg Res"},{"issue":"11","key":"1834_CR32","doi-asserted-by":"publisher","first-page":"5665","DOI":"10.7314\/APJCP.2012.13.11.5665","volume":"13","author":"K Wang","year":"2012","unstructured":"Wang K, Peng HL, Li LK. Prognostic value of vascular endothelial growth factor expression in patients with prostate cancer: a systematic review with meta-analysis. Asian Pac J Cancer Prev. 2012;13(11):5665\u20139.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"35","key":"1834_CR33","doi-asserted-by":"publisher","first-page":"E3689","DOI":"10.1073\/pnas.1405801111","volume":"111","author":"J Semenas","year":"2014","unstructured":"Semenas J, Hedblom A, Miftakhova RR, et al. The role of PI3K\/AKT-related PIP5K1\u03b1 and the discovery of its selective inhibitor for treatment of advanced prostate cancer. Proc Natl Acad Sci U S A. 2014;111(35):E3689\u201398.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1834_CR34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0079-6603(00)64003-5","volume":"64","author":"AM Jetten","year":"2000","unstructured":"Jetten AM, Suter U. The peripheral myelin protein 22 and epithelial membrane protein family. Prog Nucleic Acid Res Mol Biol. 2000;64:97\u2013129.","journal-title":"Prog Nucleic Acid Res Mol Biol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-020-01834-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12916-020-01834-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-020-01834-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T02:03:57Z","timestamp":1606788237000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-020-01834-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1834"],"URL":"https:\/\/doi.org\/10.1186\/s12916-020-01834-0","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"4 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The multi-center retrospective urine study was approved by IRB at San Francisco General Hospital (IRB # 15-15816) using archived urine samples obtained from Cooperative Human Tissue Network Southern Division and Indivumed GmbH with appropriate ethical approval and patient consent before urine collection. The multi-center prospective urine study was approved by IRB at Shenzhen People\u2019s Hospital (Study Number P2014-006) to collect fresh urine samples from patients treated at seven hospitals collaborated in the study with informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Heather Johnson is an employee of Olympia Diagnostics, Inc., and inventor of a pending patent application of prostate cancer diagnostic and prognostic biomarkers. No conflict of interest or financial interest was declared by the other authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"376"}}